dominance for each cancer and these have to be circumvented. So far after one year of clinical trial treatment on the combined pill, Dabrafenib and Trametinib, 41% of melanoma patients were progress-free compared with only 9% in the monotherapy Dabrafenib arm. The inhibitor combination also reduced the re

combined cancer inhibitor drugs as a single pill. Last January 2014, the FDA approved the first combined inhibitor drug for melanoma: Dabrafcnib and Trametinib, designed to block certain BRAF enzyme pathway mutations and resistant mutations. In July 2014, the FDA approved combined inhibitors idelaisib and